Andrographis Andrographis paniculata (Burm.f.) Wall. ex Nees
Also called: kalmegh, chiretta, Indian echinacea, chuan xin lian
Andrographis is a bitter-tasting annual plant common across much of Asia and used in traditional Indian and Chinese medicine. Products and trial preparations are mostly commercial extracts, used alone or combined with other herbs.
- Category
- Botanical
- Part used
- Plant extracts; trials mostly used commercial products, alone or in herbal mixtures
- Strongest evidence
- B Some positive trials
- Native range
- Native to the Indian Subcontinent (POWO lists Assam, Bangladesh, India, Nepal, Sri Lanka and West Himalaya); introduced elsewhere in tropical Asia, the Pacific and the Americas
- Reviewed
- 2026-10-29
Class 1 Well studied in people. A 2021 systematic review and meta-analysis (Pharmacoepidemiol Drug Saf) of oral Andrographis paniculata monotherapy pooled adverse-event incidence from 10 RCTs, plus 3 intensive-monitoring studies. The count covers safety outcomes in respiratory infection, non-infective diarrhea and autoimmune disease. [6]
Fact-checked 2026-10-29 · How this guide is made
Education, not medical advice. These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure or prevent any disease, or to replace any medication or medical advice. EUTECNIQ sells no supplements today, and this page links to no product. Supplements can interact with medicines; ask a doctor or pharmacist before use, especially in pregnancy, while breastfeeding, before surgery or for a child.
What research has studied
Grades describe the human evidence in the cited sources, not a recommendation. A means consistent randomized trials; X means good trials found no effect.
BSeveral areas, whole body or blood1 topic
CLungs and airways1 topic
CHeart and blood vessels1 topic
CStomach and gut1 topic
CBones and joints1 topic
A consistent trialsB some positive trialsC limited human evidenceD lab or animal onlyX no effect in good trials
| Topic studied | Grade | What the evidence shows |
|---|---|---|
| Symptoms of acute respiratory tract infections (colds, sore throat, cough) | B | A 2017 meta-analysis of 33 RCTs (7,175 patients) found improved cough and sore throat versus placebo and shorter symptom duration versus usual care; overall trial quality was poor. [2] |
| Mild-to-moderate COVID-19 | C | A 2025 meta-analysis of six RCTs (660 adults) found no significant improvement in fever or cough resolution, CRP or IL-6 versus antivirals or supportive care. [3] |
| Ulcerative colitis | C | In one trial, higher-dose extract produced more clinical responses than placebo; another found it comparable to mesalamine. MSK says additional studies are needed to confirm these effects. [1] |
| Rheumatoid arthritis symptoms | C | Small trials suggested reduced rheumatoid factors and arthritis symptoms; MSK states additional studies are needed to confirm these effects. [1] |
| Triglycerides in adults with modestly raised levels | C | One trial reported triglyceride reductions with a high-dose extract comparable to gemfibrozil. [1] |
Main constituents: Diterpenoid lactones known as andrographolides, described as the active constituents [1]
Amounts studied and limits
Amounts used in research, not dosing advice. Products differ in form and strength; a clinician can advise on an individual dose.
- A human pharmacokinetic study gave four tablets of a fixed combination (Kan Jang) as a single dose equal to 20 mg andrographolide; the stated regimen was 3 x 4 tablets a day (about 1 mg andrographolide/kg/day). [4]
No official upper intake level has been set.
Safety and side effects
- Liver (NIH LiverTox)See details
No LiverTox chapter found. In COVID-19 trials, mild adverse events were mainly liver enzyme elevations that resolved without severe complications.
Details and sources - Pregnancy and breastfeedingNothing found
No published information found in the sources checked.
Details and sources - Interactions with medicines6 listed
Blood pressure-lowering drugs; Anticoagulants and antiplatelet drugs; CYP1A2, CYP2C9 and CYP3A4 substrates; Aminophylline; Chemotherapy drugs …
Details and sources - Cancer evaluations (IARC, NTP)None found
No IARC or NTP evaluation was found in the lists checked.
Details and sources - FDA new dietary ingredient notificationsNone on FDA's list
FDA does not approve dietary supplements. Each entry is one party's filing.
Details and sources - Dose in official monographsNone found
No published information found in the sources checked.
Details and sources
- Anaphylaxis: Australia's TGA received 254 anaphylaxis reports linked to andrographis from 2005 to 31 December 2024 (184 of them in 2019-2024), including one fatal case reported in June 2024. [5]
- TGA found most cases occurred on first exposure or after earlier uneventful use, usually within 30 minutes, and concluded the risk cannot be predicted or reliably mitigated. [5]
- Reported side effects include headache, fatigue, dizziness, rash and other allergic reactions, lymph node pain or swelling, nausea, vomiting, diarrhea and altered taste. [1]
- Acute kidney injury has been reported after intravenous andrographolides; andrographis may elevate liver enzymes. [1]
- A 2021 meta-analysis estimated serious adverse events at 0.02 per 1,000 patients and nonserious events (mainly gastrointestinal and skin) at 102.6 per 1,000 in RCTs. [6]
Interactions
| With | What happens |
|---|---|
| Blood pressure-lowering drugs | Possible additive blood pressure lowering; healthy volunteers taking the usual cold dose showed transient blood pressure reductions. [1] |
| Anticoagulants and antiplatelet drugs | Lab studies show inhibited platelet aggregation, while a rat study found no interaction with warfarin; MSK advises caution. [1] |
| CYP1A2, CYP2C9 and CYP3A4 substrates | Extract inhibited these enzymes in lab studies; clinical relevance is not determined. [1] |
| Aminophylline | Andrographis inhibits CYP1A2, which metabolizes aminophylline, raising the risk of its side effects (preclinical studies). [1] |
| Chemotherapy drugs | Antioxidant effects of andrographolides may interfere with some chemotherapy drugs. [1] |
| UGT2B7 substrates | Lab studies suggest andrographolide derivatives inhibit UGT2B7 and could increase side effects of drugs it metabolizes. [1] |
Tell a pharmacist or doctor about every supplement you take. All documented interactions in this hub.
Identity, quality and standardization
Regulatory status
- US: FDA states that, by law, it does not approve dietary supplements or their labeling; under DSHEA it has no authority to approve them before they are marketed, and firms are responsible for their products' safety and labeling. [7]
- Australia: a label warning has been required since 2019; a strengthened warning used for one product from 2024 did not reduce reports, and TGA's March 2026 review found andrographis may not be appropriately positioned in low-risk listed medicines. [5]
Safety, quality and supply profile
Fourteen questions a careful buyer, formulator or clinician would ask, each answered only from a cited source (checked 2026-10-29). If our sources do not answer a question, we say so.
Compounds responsible
Compounds the sources name as the main or characteristic actives.
- Andrographolides Diterpenoid lactones [P1]
US status
What FDA's published records show. FDA does not approve dietary supplements.
- No NDI notification naming andrographis (Andrographis paniculata) was found in FDA's published NDI list (dated July 9, 2026; checked 2026-10-29). FDA keeps no authoritative list of ingredients marketed before October 15, 1994. [P2]
Cancer evaluations (IARC and NTP)
Evaluations name the exact material tested, which may differ from a supplement.
- No IARC or NTP carcinogenicity evaluation of andrographis was found (IARC Monographs list of classifications and NTP technical reports checked 2026-10-29). [P3]
Liver (NIH LiverTox)
- No LiverTox chapter found. In COVID-19 trials, mild adverse events were mainly liver enzyme elevations that resolved without severe complications. [P4]
Interactions with medicines
- Blood pressure-lowering drugs: Possible additive blood pressure lowering; healthy volunteers taking the usual cold dose showed transient blood pressure reductions. [P1]
- Anticoagulants and antiplatelet drugs: Lab studies show inhibited platelet aggregation, while a rat study found no interaction with warfarin; MSK advises caution. [P1]
- CYP1A2, CYP2C9 and CYP3A4 substrates: Extract inhibited these enzymes in lab studies; clinical relevance is not determined. [P1]
- Aminophylline: Andrographis inhibits CYP1A2, which metabolizes aminophylline, raising the risk of its side effects (preclinical studies). [P1]
- Chemotherapy drugs: Antioxidant effects of andrographolides may interfere with some chemotherapy drugs. [P1]
- UGT2B7 substrates: Lab studies suggest andrographolide derivatives inhibit UGT2B7 and could increase side effects of drugs it metabolizes. [P1]
Alcohol
- No published information found in the sources checked.
Interactions with other herbs and supplements
- No published information found in the sources checked.
Adulteration and substitution
- No published information found in the sources checked.
What a certificate of analysis should cover
Tests a quality specification for this material would include, with the reason for each.
- Identity test or examination of each dietary-ingredient component before use — 21 CFR 111.75(a)(1)(i) requires at least one appropriate identity test or examination unless FDA grants an exemption petition under 111.75(a)(1)(ii). [P5]
Supply and conservation
- No published information found in the sources checked.
Absorption in people
- After four Kan Jang tablets (20 mg andrographolide), plasma andrographolide peaked at about 393 ng/ml at 1.5-2 hours; half-life was 6.6 hours. [P6]
Formulations studied to change absorption
Human data only.
- No published information found in the sources checked.
Dose in official monographs
As the monograph states it, for its jurisdiction; not personal advice.
- No published information found in the sources checked.
Pregnancy and breastfeeding
- No published information found in the sources checked.
Sources for this profile
- Memorial Sloan Kettering Cancer Center. About Herbs: Andrographis (last updated December 16, 2021), 2021-12-16. mskcc.org
- FDA. Submitted 75-Day Premarket Notifications for New Dietary Ingredients (list dated July 9, 2026), 2026-07-09. fda.gov
- IARC Monographs on the Identification of Carcinogenic Hazards to Humans. List of Classifications (checked 2026-10-29), 2026-10-29. monographs.iarc.who.int
- Prabhakornritta P, et al. Exploring the clinical effects of Andrographis paniculata-derived compounds, its extract, or derivatives for the treatment of COVID-19: a systematic review and meta-analysis. Front Pharmacol 2025;16:1598255 (PMID 40822451), 2025-07-31. pubmed.ncbi.nlm.nih.gov
- eCFR. 21 CFR 111.75, What must you do to determine whether specifications are met? (current text, checked 2026-10-29), 2026-10-29. ecfr.gov
- Panossian A, et al. Pharmacokinetic and oral bioavailability of andrographolide from Andrographis paniculata fixed combination Kan Jang in rats and human. Phytomedicine 2000;7(5):351-364 (PMID 11081986), 2000-10. pubmed.ncbi.nlm.nih.gov
Sources
- Memorial Sloan Kettering Cancer Center. About Herbs: Andrographis (last updated December 16, 2021), 2021-12-16. mskcc.org
- Hu XY, et al. Andrographis paniculata (Chuan Xin Lian) for symptomatic relief of acute respiratory tract infections in adults and children: a systematic review and meta-analysis. PLoS One 2017;12(8):e0181780 (PMID 28783743), 2017-08-04. pubmed.ncbi.nlm.nih.gov
- Prabhakornritta P, et al. Exploring the clinical effects of Andrographis paniculata-derived compounds, its extract, or derivatives for the treatment of COVID-19: a systematic review and meta-analysis. Front Pharmacol 2025;16:1598255 (PMID 40822451), 2025-07-31. pubmed.ncbi.nlm.nih.gov
- Panossian A, et al. Pharmacokinetic and oral bioavailability of andrographolide from Andrographis paniculata fixed combination Kan Jang in rats and human. Phytomedicine 2000;7(5):351-364 (PMID 11081986), 2000-10. pubmed.ncbi.nlm.nih.gov
- Therapeutic Goods Administration (Australia). Andrographis paniculata (Andrographis) and anaphylaxis: updated safety review with adverse event data to 31 December 2024 (Version 1.0, March 2026), 2026-03. tga.gov.au
- Worakunphanich W, et al. Safety of Andrographis paniculata: a systematic review and meta-analysis. Pharmacoepidemiol Drug Saf 2021;30(6):727-739 (PMID 33372366), 2021-06. pubmed.ncbi.nlm.nih.gov
- U.S. Food and Drug Administration. Questions and Answers on Dietary Supplements (content current as of 08/27/2026), 2026-08-27. fda.gov
- Plants of the World Online (POWO), Royal Botanic Gardens, Kew; WCVP data. Andrographis paniculata (Burm.f.) Wall. ex Nees (accessed 2026-10-29), 2026-10-29. powo.science.kew.org
- A
- Consistent results from several randomized trials or a systematic review of them
- B
- Some positive randomized trials, but small, short, few or inconsistent
- C
- Limited human evidence: single small trials, observational data or mixed results
- D
- Laboratory or animal evidence only; not shown in people
- X
- Well-designed human trials found no meaningful effect
More in botanical: Aloe vera · American ginseng · Amla · Arjuna · Arnica · Aronia (black chokeberry) · Asafoetida · Ashwagandha · All entries A–Z · How to judge a supplement
Health information notice
These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease. The information is for general education only. It is not medical advice and does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed.
Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.
EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.